Cerebrospinal fluid monoamines in Prader-Willi syndrome

Biological Psychiatry

Volumn 44, Issue 12, 1998, Pages 1321-1328

  Åkefeldt, Arne ^a   Ekman, Rolf ^a   Gillberg, Christopher ^a   Månsson, Jan Eric ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Behavior; Cerebrospinal fluid; Dopamine; Neurochemistry; Prader Willi syndrome; Serotonin

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; 5 HYDROXYINDOLEACETIC ACID; DOPAMINE; FENFLURAMINE; HOMOVANILLIC ACID; SEROTONIN; SEROTONIN UPTAKE INHIBITOR;

ADOLESCENT; ARTICLE; AUTISM; BODY WEIGHT; CEREBROSPINAL FLUID; CHILD; CHILD BEHAVIOR; CHILD PSYCHIATRY; CHILDHOOD DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; INTELLIGENCE QUOTIENT; MALE; OBESITY; PRADER WILLI SYNDROME; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGE FACTORS; AUTISTIC DISORDER; BIRTH WEIGHT; BODY MASS INDEX; CHILD; CHILD, PRESCHOOL; FEMALE; HOMOVANILLIC ACID; HUMANS; HYDROXYINDOLEACETIC ACID; INFANT; INTELLIGENCE TESTS; MALE; METHOXYHYDROXYPHENYLGLYCOL; NEUROTRANSMITTER AGENTS; OBESITY; PHENOTYPE; PRADER-WILLI SYNDROME;

EID: 0032535589     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(97)00519-2     Document Type: Article

References (66)

1. Ågren H. Biological Markers in Major Depressive Disorders. 1981;Acta Universitas Upsaliensis, Uppsala, Sweden.
2. Åkefeldt A (1992): Behaviour in Prader-Willi syndrome - Variations in the phenotype with age. Society for the Study of Behavioural Phenotype 2nd International Symposium "From Genes to Behaviour." Welshpool, U.K., November 19-21.
3. Åkefeldt A., Gillberg C., Larsson C. Prader-Willi syndrome in a Swedish rural county Epidemiological aspects . Dev Med Child Neurol. 33:1991;715-721.
4. Åkefeldt A., Anvret M., Grandell U., Nordlinder R., Gillberg C. Parental exposure to hydrocarbons in Prader-Willi syndrome. Dev Med Child Neurol. 37:1995;1101-1109.
5. Aou S., Mizuno M., Hori T., Yamada K. The effect of B-HT 920, a dopamin D2 agonist, on bar-press feeding in the monkey. Physiol Behav. 55:1994;1125-1130.
6. Baker P., Piven J., Schwartz S., Patil S. Brief report Duplication of chromosome 15q11-13 in two individuals with autistic disorder . J Autism Dev Disord. 24:1994;529-535.
7. Barlow D.P. Methylation and imprinting From host defense to gene regulation? Science. 260:1993;309-310.
8. Blennow K., Wallin A., Gottfries C.G., Månsson J.-E., Svennerholm L. Concentration gradients for monoamine metabolites in lumbar cerebrospinal fluid. J Neural Transm. 5:1993;5-15.
9. Blennow K., Wallin A., Gottfries C.G., Karlsson M. I, ånsson J.-E., Skoog I., et al. Cerebrospinal fluid monoamine metabolites in 114 healthy individuals 18-88 years of age. Eur Neuropsychopharmacol. 3:1993;55-61.
10. Bradley J.W. Distribution-Free Statistical Tests. 1968;68-86 Prentice-Hall, London.
11. Burd L., Vesely B., Martsolf J., Kerbeshian J. Prevalence study of Prader-Willi syndrome in North Dakota. Am J Med Genet. 37:1990;97-99.
12. Butler M.G. Hypopigmentation A common feature of Prader-Labhart-Willi syndrome . Am J Hum Genet. 45:1989;140-146.
13. Butler M.G., Meaney F.J. Standards for selected anthropometric measurements in Prader-Willi syndrome. Pediatrics. 88:1991;853-860.
14. Cassidy S.B. Prader-Willi syndrome. Curr Probl Pediatr. 14:1984;1-55.
15. Cassidy SB, McKillop JA, Morgan MS (1989): Sleep disorders in Prader-Willi syndrome. 4th Annual Prader-Willi Syndrome Scientific Conference. Marlborough Inn, Calgary, Alberta, Canada, July 19.
16. Cassidy S.B., Forsythe M., Heeger S., Nicholls R.D., Schork N., Benn P., et al. Comparisons of phenotype between patients with Prader-Willi syndrome due to deletion 15q and uniparental disomy 15. Am J Med Genet. 68:1997;433-440.
17. Cervo L., Rossi C., Tatarczynska E., Samanin R. Role of 5-HT1A receptors in the antinociceptive action of 8-hydroxy-2-(di-n-propylamino)tetralin in the rat. Eur J Pharmacol. 263:1994;187-191.
18. Clarke DJ (1988): Abnormalities of sleep and behaviour among adults with Prader-Willi syndrome. Paper presented at the 16th International Study Group in Child Neurology and Cerebral Palsy. Cambridge, September.
19. Curfs L.M.G., Verhulst F.C., Fryns J.P. Behavioral and emotional problems in youngsters with Prader-Willi syndrome. Genet Couns. 2:1991;33-41.
20. Dech B., Budow L. The use of fluoxetine in an adolescent with Prader-Willi syndrome. J Am Acad Child Adolesc Psychiatry. 30:1991;298-302.
21. Dittrich B., Robinson W.P., Knoblauch H., Buiting K., Schmidt K., Gillessen-Kaesbach G., et al. Molecular diagnosis of the Prader-Willi and Angelman syndromes by detection of parent-of-origin specific DNA methylationn 15q11-13. Hum Genet. 90:1992;313-315.
22. Driscoll D.J., Waters M.F., Williams C.A., Zori R.T., Glenn C.C., Avidano K.M., et al. A DNA methylation imprint, determined by the sex of the parent, distinguishes the Angelman and Prader-Willi syndromes. Genomics. 13:1992;917-924.
23. Dykens E.M., Leckman J.F., Cassidy S.B. Obsessions and compulsions in Prader-Willi Syndrome. J Child Psychol Psychiat. 37:1996;995-1002.
24. Ellinwood E.H., Rockwell W.J.K. Central nervous system stimulants and anorectic agents. Dukes M.N.G. Meyler's Side Effects of Drugs. 11th ed. 1988;1-26 Elsevier Science Publications B.V, Amsterdam.
25. Ensler K., Ryan C.N., Evenden J.L. Effects of repeated treatment with 5-HT1A agonists on active avoidance responding in the rat. Psychopharmacology. 112:1993;45-54.
26. Geracioti T.D., Liddle R.A. Impaired cholecystokinin secretion in bulimia nervosa. N Engl J Med. 319:1988;683-688.
27. Gillberg C., Svennerholm L. CSF monoamines in autistic syndromes and other pervasive developmental disorders of early childhood. Br J Psychiatry. 151:1987;89-94.
28. Gillberg C., Svennerholm L., Hamilton-Hellberg C. Childhood psychosis and monoamine metabolites in spinal fluid. J Autism Dev Disord. 13:1983;383-396.
29. Gillessen-Kaesbach G., Robinson W., Lohman D., Kaya-Westerloh S., Passarge E., Horsthemke B. Genotype-phenotype correlation in a series 167 deletion and nondeletion patients with Prader-Willi syndrome. Hum Genet. 96:1995;638-643.
30. Goodall E.M., Cowen P.J., Franklin M., Silverstone T. Ritanserin attenuates anorectic, endocrine and thermic responses to d-fenfluramine in human volunteers. Psychopharmacology. 112:1993;461-466.
31. Greenswag L.R. Adults with Prader-Willi syndrome A survey of 232 cases . Dev Med Child Neurol. 29:1987;145-152.
32. Greenswag L (1995): Long term follow-up of use of Prozac as a behavioral management intervention in 57 persons with PWS. 2nd Prader-Willi Syndrome International Scientific Workshop and Conference. Sörmarka, Oslo, Norway, June 15-18.
33. Grignaschi G., Samanin R. Role of serotonin receptors in the effect of sertraline on feeding behaviour. Psychopharmacology. 110:1993;203-208.
34. Hellings J.A., Warnock J.K. Self-injurious behavior and serotonin in Prader-Willi syndrome. Psychopharmacol Bull. 30:1994;245-250.
35. Holm V.A. The diagnosis of Prader-Willi syndrome. Holm V.A., Sulzbacher S.J., Pipes P.L. Prader-Willi Syndrome. 1981;27-44 University Park Press, Baltimore.
36. Holm V.A., Cassidy S.B., Butler M.G., Hanchett J.M., Greenswag L.R., Whitman B.Y., et al. Prader-Willi syndrome Consensus diagnostic criteria . Pediatrics. 91:1993;398-402.
37. Hoyer D., Clarke D.E., Fozard J.R., Hartig P.R., Martin G.R., Mylecharane E.J., et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev. 46:1994;157-203.
38. Kaye W.H., Gwirtsman H.E., George D.T., Ebert M.H. Altered serotonin activity in anorexia nervosa after long-term weight restoration. Does elevated cerebrospinal fluid 5-hydroxyindoleacetic acid level correlate with rigid and obsessive behavior? Arch Gen Psychiatry. 48:1991;556-562.
39. Knoll J.H.M., Wagstaff J., Lalande M. Cytogenetic and molecular studies in the Prader-Willi and Angelman syndromes An overview . Am J Med Genet. 46:1993;2-6.
40. Knoll J.H.M., Sinnett D., Wagstaff J., Glatt K., Wilcox A.S., Whiting P.M., et al. FISH ordering of the reference markers and of the gene for the α5 subunit of the γ-aminobutyric acid receptor (GABRA5) within the Angelman and Prader-Willi syndrome chromosomal regions. Hum Mol Genet. 2:1993;183-189.
41. Ledbetter D.H., Riccardi V.M., Airhart S.D., Strobel R.J., Keenan S.B., Crawford J.D. Deletions of chromosome 15 as a cause of the Prader-Willi Syndrome. N Engl J Med. 304:1981;325-329.
42. Ledbetter D.H., Mascarello J.T., Riccaardi V.M., Harper V.D., Airhart S.D., Strobel R.J. Chromosome 15 abnormalities and the Prader-Willi syndrome A follow-up report of 40 cases . Am J Hum Genet. 34:1982;278-285.
43. Leibowitz S.F. Brain monoamines and peptides Role in the control of eating behavior . Fed Proc. 45:1986;1396-1403.
44. Leibowitz S.F. The role of serotonin in eating disorders. Drugs. 39:(suppl 3):1990;33-48.
45. Mantel N. Chi-square tests with one degree of freedom Extensions of the Mantel-Haenszcl procedure . J Am Stat Assoc. 58:1963;690-700.
46. Mascari M.J., Gottlieb W., Rogan P.K., Butler M.G., Waller D.A., Armour J.A., et al. The frequency of uniparental disomy in Prader-Willi syndrome. N Engl J Med. 326:1992;1599-1607.
47. Nelson R.A., Huse D.M., Holman R.T., Kimbrough B.O., Wahner H.W., Callaway C.W., et al. Nutrition, metabolism, body composition, and response to the ketogenic diet in Prader-Willi syndrome. Holm V.A., Sulzbacher S.J., Pipes P.L. Prader-Willi Syndrome. 1981;105-120 University Park Press, Baltimore.
48. Nicholls R.D., Knoll J.M.H., Butler M.G., Karam S., Lalande M. Genetic imprinting suggested by maternal heterodisomy in nondeleted Prader-Willi syndrome. Nature. 342:1989;281-285.
49. Paez X., Leibowitz S.F. Changes in extracellular PVN monoamines and macronutrient intake after idazoxan or fluoxetine injection. Pharmacol Biochem Behav. 46:1993;933-941.
50. Phillips G.D., Howes S.R., Whitelaw R.B., Robbins T.W., Everitt G.J. Analysis of the effects of intra-accumbens SKF-38393 and LY-171555 upon the behavioural satiety sequence. Psychopharmacology. 117:1995;82-90.
51. Pinder R.M., Brogden R.N., Sawyer P.R., Speight T.M., Avery G.S. Fenfluramine A revue of its pharmacologic properties and therapeutic efficacy in obesity . Drugs. 10:1975;244-323.
52. Prader A., Labhart A., Willi H. Ein Syndrom von Adipositas, Kleinwuchs, Kryptorchismus und Oligophrenie nach muotonieartigem Zustand in Neugeboren alter. Schweiz Med Wochensch. 86:1956;260-261.
53. Reis A., Dittrich B., Greger V., Buiting K., Lalande M., Gillessen-Kaesbach G., et al. Imprinting mutations suggested by abnormal DNA methylation pattern in familial Angelman and Prader-Willi syndromes. Am J Hum Genet. 54:1994;741-747.
54. Sánchez C., Arnt J., Hyttel J., Moltzen E.K. The role of serotonergic mechanisms in inhibition of isolation-induced aggression in male mice. Psychopharmacology. 110:1993;53-59.
55. Selikowitz M., Sunman J., Pendergast A., Wright S. Fenfluramine in Prader-Willi syndrome A double blind, placebo controlled trial . Arch Dis Child. 65:1990;112-114.
56. Strömbom U., Krotkiewski M., Blennow K., Månsson J.-E., Ekman R., Björntorp P. The concentration of monoamine metabolites and neuropeptides in the cerebrospinal fluid of obese women with different body fat distribution. Int J Obes Relat Metab Disord. 20:1996;361-368.
57. Swahn C.G., Sandgärde B., Wiesel F.A., Sedvall G. Simultaneous determination of the three major metabolites in brain tissue and body fluids by mass fragmentographic method. Psychopharmacology. 48:1976;147-152.
58. Swain J.L., Steward T.A., Leder P. Parental legacy determines methylation and expression of an autosomal transgene A molecular mechanism for parental imprinting . Cell. 50:1987;719-727.
59. Takahashi A., Ishimaru H., Ikarashi Y., Maruyama Y. Decrease of norepinephrine and preservation of acetylcholine in the hypothalamus of VMH obese rats. Brain Res Bull. 36:1995;97-99.
60. Taylor R.L., Caldwell M.L. Type and strength of food preferences of individuals with Prader-Willi syndrome. J Ment Defic Res. 29:1985;109-112.
61. Thombre D.P., Krishnamurthy N., Pal G.K. Effects of different feeding schedules on food intake in caudate lesioned rats. Indian J Physiol Pharmacol. 38:1994;313-315.
62. Trygstad OE (1995): Pharmacological control of appetite. 2nd Prader-Willi Syndrome International Scientific Workshop and Conference, Sörmarka, Oslo, Norway, June 15-18.
63. Wenger S.L., Rauch S.D., Hanchett J.M. Sister chromatide exchange analysis of the 15q11 region in Prader-Willi syndrome patients. Hum Genet. 83:1989;111-114.
64. Whitman B.Y., Acardo P. Emotional symptoms in Prader-Willi syndrome adolescents. Am J Med Genet. 28:1987;897-905.
65. Wisniewski L.P., Witt M.E., Ginsberg-Fellner F., Wilner J., Desnick R.J. Prader-Willi syndrome and a bisatellited derivative of chromosome 15. Clin Genet. 18:1980;42-47.
66. Young K.A., Zavodny R., Hicks P.B. Effects of serotonergic agents on apo-morphine-induced locomotor activity. Psychopharmacology. 110:1993;97-102.